7.98
Atrium Therapeutics Inc Borsa (RNA) Ultime notizie
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing - TradingView
Atrium Therapeutics Announces $50 Million Private Placement - Investing News Network
Atrium Therapeutics Secures $50 Million Private Placement to Advance RNA-Based Cardiology Pipeline - citybiz
Atrium Therapeutics Raises About $50 Million in PIPE at $7.93; Adds Pre-Funded Warrants - TradingView
Atrium Therapeutics Secures Nearly $50 Million Through October 2026 PIPE Offering - Kalkine Media
Atrium Therapeutics Announces $50 Million Private Placement - PR Newswire
Atrium Therapeutics Announces $50 Million Private Placement - Stock Titan
Why is Atrium Therapeutics stock surging today? - Investing.com
Atrium Therapeutics raises $50 million in private placement - Investing.com
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com - Investing.com Canada
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com - Investing.com Nigeria
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Atrium Therapeutics CMO Steven George Hughes Reports Tax-Related Share Withholding on RSU Vesting - Kalkine Media
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Atrium Therapeutics Inc For: 22 September - Investing.com India
Atrium Therapeutics (RNA) CSO now holds 41K shares after RSU tax withholding - Stock Titan
21K Atrium Therapeutics (RNA) shares withheld for CMO's taxes - Stock Titan
Director at Atrium Therapeutics (RNA) has 22,812 shares withheld for taxes - Stock Titan
Tax withholding trims Atrium Therapeutics (RNA) director's stake - Stock Titan
2,375 Atrium Therapeutics (RNA) shares withheld for taxes - Stock Titan
Tax withholding trims 11,632 Atrium Therapeutics (RNA) shares, not a market sale - Stock Titan
Atrium Therapeutics (RNA) executive now holds 38,340 shares after tax move - Stock Titan
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics - Stock Titan
Atrium Therapeutics, Inc.Common Stock (Nasdaq:RNA) Price Chart - The Chronicle-Journal
Atrium Therapeutics at Wells Fargo conference: heart-rna push gains pace - Investing.com Nigeria
Atrium Therapeutics at Wells Fargo conference: heart-rna push gains pace - Investing.com Canada
Atrium Therapeutics, Inc. (RNA): Analyst Consensus Highlights 76% Potential Upside for Biotechnology Innovator - DirectorsTalk Interviews
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real - Yahoo Finance
Atrium Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Atrium Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
The FDA cleared Atrium’s application to test a heart treatment. The company will join three September conferences. - Stock Titan
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform? - Yahoo Finance
Atrium Therapeutics, Inc. Share Price Live Today – NASDAQ:RNA Stock Price, Chart, News, History - upstox.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Player with a Potential 89% Upside - DirectorsTalk Interviews
BRIEF-Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - Dailyhunt
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units - Stock Titan
Atrium (RNA) Momentum: Records a 1.68% Decrease to $13.48; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingBreakaway Gap - vinanet.vn
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingStop Loss Guidance - vinanet.vn
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneDark Pool Sentiment - vinanet.vn
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneGap Up Stocks - dars.gov.et
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingADD Alert - careplusvn.com
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCup and Handle - dars.gov.et
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCounter Trend Trade - Vinanet
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportSentiment Divergence - siam.in
Atrium Therapeutics (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentDividend Earnings Report - vinanet.vn
Atrium Therapeutics (RNA) Jumps 4.14% to $12.84 as Buyers Defend Key SupportValue Area High - vinanet.vn
Atrium Therapeutics (RNA) Climbs 4.1% to $12.84 as Biotech Sentiment StrengthensLow Beta Factor - Vinanet
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):